EMEA-001251-PIP01-11-M05
Key facts
| Invented name |
Imlygic
|
| Active substance |
talimogene laherparepvec
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0005/2022
|
| PIP number |
EMEA-001251-PIP01-11-M05
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Treatment of melanoma
|
| Route(s) of administration |
Intralesional use
|
| Contact for public enquiries |
Amgen Europe B.V.
E-mail: pipenquiry@amgen.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|